A Controlled Study of the Effects of Alendronate in a Growing Mouse Model of Osteogenesis Imperfecta

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Calcified Tissue International

• Publication date

  2001-07-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s002230010045PMID 11683430
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alendronate in the Treatment of Osteoporosis: A Review of the Clinical Trials

  2000cited by this paper
• Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.

  2000cited by this paper
• Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

  2000cited by this paper
• Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

  1999cited by this paper
• Osteopetrosis.

  1998cited by this paper
• Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats.

  1998cited by this paper
• Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

  1998cited by this paper
• Identification of the oim mutation by dye terminator chemistry combined with automated direct DNA sequencing

  1998cited by this paper
• Osteogenesis imperfecta--managing brittle bones.

  1998cited by this paper
• Alendronate

  1997cited by this paper
• Method of histomorphometric assessment of glycosaminoglycans in articular cartilage

  1997cited by this paper
• Mutations in fibrillar collagens (types I, II, III, and XI), fibril‐associated collagen (type IX), and network‐forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels

  1997cited by this paper
• Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta.

  1996cited by this paper
• Bisphosphonates: a review of their pharmacokinetic properties.

  1996cited by this paper
• Long-term effects of clodronate on growing rat bone.

  1996cited by this paper
• Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones.

  1996cited by this paper
• Effects of large doses of olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture, and mechanical properties of rat femurs.

  1995cited by this paper
• Bisphosphonate on bones

  1995cited by this paper
• Confirmation of a G nucleotide deletion in the Cola-2 gene of mice with the osteogenesis imperfecta mutation.

  1994cited by this paper
• Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta.

  1993cited by this paper
• Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

  1973cited by this paper
• New approaches to treatment of osteogenesis imperfecta.

  1973cited by this paper

• Fracturas femorales atípicas en una cohorte mexicana de niños y adolescentes con osteogénesis imperfecta. Análisis de trayectorias

  2025cites this paper
• A Siglec‐15 Antibody Promotes High Quality Bone Formation in Adult Female Mice With Osteogenesis Imperfecta

  2025cites this paper
• Combined Treatment with a C-Type Natriuretic Peptide Analog and Bisphosphonate Enhances Bone Growth in Growing Mice with Osteogenesis Imperfecta: A Pilot Study.

  2025cites this paper
• Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

  2024cites this paper
• Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life

  2022cites this paper
• An Update on Animal Models of Osteogenesis Imperfecta

  2022cites this paper
• Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta

  2021cites this paper
• Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice

  2020cites this paper
• Changes in Biomaterial Properties of Bone With Disease and Treatment

  2020cites this paper
• Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.

  2019cites this paper
• Clinical pathologies of bone fracture modelled in zebrafish

  2019cites this paper
• An update on the role of RANKL–RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases

  2018cites this paper
• Micro-computed tomography reconstructions of tibiae of stem cell transplanted osteogenesis imperfecta mice

  2018cites this paper
• Prophylactic Bisphosphonate Therapy to Reduce Glucocorticoid-Induced Osteoporosis in a Mouse Model of Duchenne Muscular Dystrophy

  2018cites this paper
• Low Dose of Bisphosphonate Enhances Sclerostin Antibody‐Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model

  2018cites this paper
• Drug-induced Physeal Abnormalities in Preclinical Toxicity Studies

  2017cites this paper
• Denosumab and surgery for the treatment of Perthes’ disease in a 9-year-old boy: favorable course documented by comprehensive imaging— a case report

  2017cites this paper
• Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice.

  2017cites this paper
• Non-destructive NIR spectral imaging assessment of bone water: Comparison to MRI measurements.

  2017cites this paper
• Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α

  2016cites this paper
• Bisphosphonate therapy for osteogenesis imperfecta.

  2016cites this paper
• Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.

  2016cites this paper
• Counteracting bone fragility with human amniotic mesenchymal stem cells

  2016cites this paper
• The Effect of Stontium Ranelate on Fracture Reduction in Osteogenesis Imperfecta is Comparable to Recent Bisphosphonate Data

  2016cites this paper
• Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.

  2016cites this paper
• Local Administration of Bisphosphonate-soaked Hydroxyapatite for the Treatment of Osteonecrosis of the Femoral Head in Rabbit

  2016cites this paper
• Response to Comment on Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta

  2016influential citation
• Treatment options for osteogenesis imperfecta

  2015influential citation
• Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?

  2015cites this paper
• Treatment of osteogenesis imperfecta in adults.

  2014cites this paper
• Beneficial Effect of Cissus quadrangularis Linn. on Osteopenia Associated with Streptozotocin-Induced Type 1 Diabetes Mellitus in Male Wistar Rats

  2014cites this paper
• Animal Models of Osteogenesis Imperfecta

  2014cites this paper
• Bisphosphonate therapy for osteogenesis imperfecta.

  2014cites this paper
• Developing medical therapy for legg-calvé- perthes’ disease

  2014cites this paper
• The effect of zoledronic acid on growth plates and high turnover bones.

  2014cites this paper
• Gender-Dependence of Bone Structure and Properties in Adult Osteogenesis Imperfecta Murine Model

  2013cites this paper
• osteogenesis imperfecta mice from first-trimester blood repairs bone and reduces fractures in Intrauterine transplantation of human fetal mesenchymal stem cells

  2013cites this paper
• Microdamage: Its Role in the Mechanical Integrity of Low Bone Mass Diseases and its Treatment Implications

  2013cites this paper
• High- and low-dose OPG–Fc cause osteopetrosis-like changes in infant mice

  2012cites this paper
• Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta

  2012influential citation
• Evidence for Using Bisphosphonate to Treat Legg-Calvé-Perthes Disease

  2012cites this paper
• Bisphosphonate therapy in children

  2012cites this paper
• Potential for Bisphosphonate Treatment in Legg-Calve-Perthes Disease

  2011cites this paper
• Intravenous Pamidronate Treatment Improves Growth in Prepubertal Osteogenesis Imperfecta Patients

  2011cites this paper
• Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient

  2011cites this paper
• Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice

  2010cites this paper
• RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta

  2010cites this paper
• Type I osteogenesis imperfecta and multiple osteochondromas in the same child.

  2009cites this paper
• Potential implications of cell therapy for osteogenesis imperfecta.

  2009cites this paper
• Use of bisphosphonates in the treatment of pediatric osteoporosis

  2009cites this paper
• Alendronate Treatment of the Brtl Osteogenesis Imperfecta Mouse Improves Femoral Geometry and Load Response Before Fracture but Decreases Predicted Material Properties and Has Detrimental Effects on Osteoblasts and Bone Formation

  2009cites this paper
• Genetic Collagen Diseases: Influence of Collagen Mutationson Structure and Mechanical Behavior

  2008cites this paper
• Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation.

  2008cites this paper
• Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

  2008cites this paper
• The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta

  2008cites this paper
• Bisphosphonate therapy for osteogenesis imperfecta.

  2008cites this paper
• Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice.

  2008cites this paper
• Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats

  2008cites this paper
• Animal models of osteogenesis imperfecta and related syndromes

  2007cites this paper
• [Treatment of osteogenesis imperfecta with bisphosphonates].

  2007cites this paper
• Alendronate therapy in cyclosporine-induced alveolar bone loss in rats.

  2007cites this paper
• Tratamiento de osteogenesis imperfecta con bisfosfonatos

  2007cites this paper
• Self-assembly of mineralized collagen composites

  2007cites this paper
• RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis

  2006cites this paper
• Retention, Distribution, and Effects of Intraosseously Administered Ibandronate in the Infarcted Femoral Head

  2006cites this paper
• Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge

  2006cites this paper
• CHAPTER 12 – Mineralization, Structure and Function of Bone

  2006cites this paper
• Mineralization, Structure and Function of Bone

  2006cites this paper
• THE DEVELOPMENT OF AN IN-VITRO IMMATURE ANIMAL MODEL FOR PREDICTING PEDIATRIC FEMUR FRACTURE STRENGTH

  2005cites this paper
• Transient Disturbance in Physeal Morphology Is Associated With Long‐Term Effects of Nitrogen‐Containing Bisphosphonates in Growing Rabbits

  2005cites this paper
• Emerging therapeutic approaches for osteogenesis imperfecta.

  2005cites this paper
• Effet thérapeutique de l’alendronate chez les enfants atteints d’ostéogenèse imparfaite

  2005cites this paper
• Efficacy of Oral Alendronate in Children With Osteogenesis Imperfecta

  2005cites this paper
• Effect of alendronate therapy in children with osteogenesis imperfecta.

  2005cites this paper
• Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.

  2005cites this paper
• Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.

  2005cites this paper
• Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta

  2005cites this paper
• Bisphosphonate treatment of pediatric bone disease.

  2005cites this paper
• Accuracy and precision of PIXImus densitometry for ex vivo mouse long bones: comparison of technique and software version.

  2004cites this paper
• Brittle IV Mouse Model for Osteogenesis Imperfecta IV Demonstrates Postpubertal Adaptations to Improve Whole Bone Strength

  2004influential citation
• Gene therapy approaches for osteogenesis imperfecta

  2004cites this paper
• New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.

  2003cites this paper
• Zoledronic Acid Prevents Osteopenia and Increases Bone Strength in a Rabbit Model of Distraction Osteogenesis

  2003cites this paper
• Fourier Transform Infrared Imaging Spectroscopy (FT-IRIS) of Mineralization in Bisphosphonate-treated oim/oim Mice

  2003influential citation
• Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.

  2003influential citation
• Bisphosphonate-induced osteopetrosis.

  2003cites this paper
• Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice.

  2002cites this paper
• EFFECTS OF LONG-TERM CLODRONATE ADMINISTRATION ON BONE AND ON FRACTURE HEALING IN RAT , WITH SPECIAL REFERENCE TO METHODOLOGICAL ASPECTS ANTTI KOIVUKANGAS

  2002cites this paper
• Effects of long-term clodronate administration on bone and on fracture healing in rat, with special reference to methodological aspects

  2002cites this paper
• Alendronate Treatment for Infants with Osteogenesis Imperfecta: Demonstration of Efficacy in a Mouse Model

  2002cites this paper